The Company released its preliminary half-year results for the six months period ending 30 June 2018 2018 with a reduction in its full-year guidance for the financial year ending 31 December 2018 It reported revenue of $267.2 million as compared to $294.2 million in 1HFY17 and a decline of 24 per cent in its underlying EBITDA. This was mainly due to significantly higher pulp and electricity costs of approximately $10 million, lower sales volume in the consumer tissue business, lower sales in the baby care business, ongoing investment in product quality improvements for the longer term, due to the lease cost on Springvale property in 1H18 as a result of the sale and lease back in June 2017 and due to an increase in expenditure in trade to support market share as a result of continued heavy discounting by competitors.
These results are just preliminary and remain subject to review and approval by the Audit and Risk Committee and the Board and will be reviewed by the Company’s external auditor. The Company revised its FY18 Guidance and it expects that the second half result will be weaker than the first half, contrary to historical half on half performance. Initially, the Company expected that the underlying EBITDA for FY18 will be in the range of $113-119 million but now it expects this to be between $80-85 million. The Company now anticipates that historic high pulp prices will continue in 2HFY18 and expects that pulp costs will be approximately $24 million higher year on year.
The Company will recognise material charges for impairment and write-down of assets which will be primarily non-cash once the accounts are reviewed by an external auditor. The Company is implementing initiatives from the strategic point of view to come back to a strong and sustainable position. The Company will release its half-year results on 21 August 2018. After this the stock price plunged by 32.9 per cent and the stock was trading at $0.875 (as on 17 July 2018; 03:30 PM AEST).
[pluginops_form template_id=’23834′ ]
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a company’s prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
Disclaimer
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.
Checkout our Free Dividend Stocks Report
Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.
6 Cannabis Stocks under Investor’s Limelight…
Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.
Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.
Click here for your FREE Report
